Development of Luciferase Expressing Leishmania donovani Axenic Amastigotes as Primary Model for In Vitro Screening of Antileishmanial Compounds
Authors:
- 4 September 2012
- journal article
- research article
- Published by Springer Nature in Current Microbiology
- Vol. 65 (6) , 696-700
Abstract
The development of new therapeutic leads against leishmaniasis relies primarily on screening of a large number of compounds on multiplication of clinically irrelevant transgenic promastigotes. The advent of the successful in vitro culture of axenic amastigotes allows the development of transgenic axenic amastigotes as a primary screen which can test compounds in a high throughput mode like promastigotes, still representative of the clinically relevant mammalian amastigotes stage. The present study reports the development of luciferase-tagged axenic amastigotes of Leishmania donovani, the causative agent of Indian Kala-azar, for in vitro drug screening. Luciferase expressing promastigotes were transformed to axenic amastigotes at a low pH and high temperature without the loss of luciferase expression. As compared to transgenic promastigotes, the luciferase expressing axenic amastigotes exhibited more sensitivity to antileishmanial drugs, particularly to pentavalent antimony (~2.8-fold) and also to the test compounds. Hence, the developed luciferase expressing axenic amastigotes make an ideal choice for high throughput drug screening for antileishmanial compounds.Keywords
This publication has 24 references indexed in Scilit:
- Identification of Novel Inhibitors of Dipeptidylcarboxypeptidase of Leishmania donovani via Ligand‐Based Virtual Screening and Biological EvaluationChemical Biology & Drug Design, 2011
- A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific HitPLOS Neglected Tropical Diseases, 2011
- Treatment of visceral leishmaniasisJournal of Global Infectious Diseases, 2010
- In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific DifferencesAntimicrobial Agents and Chemotherapy, 2009
- Reporter genes facilitating discovery of drugs targeting protozoan parasitesTrends in Parasitology, 2009
- Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screeningJournal of Antimicrobial Chemotherapy, 2009
- DNA Transformation of Leishmania infantum Axenic Amastigotes and Their Use in Drug ScreeningAntimicrobial Agents and Chemotherapy, 2001
- Novel Intracellular SbV Reducing Activity Correlates with Antimony Susceptibility in Leishmania donovaniJournal of Biological Chemistry, 2001
- THE ROLE OF pH AND TEMPERATURE IN THE DEVELOPMENT OF LEISHMANIA PARASITESAnnual Review of Microbiology, 1994
- An in Vitro Model for Investigation of Chemotherapeutic Agents in LeishmaniasisThe Journal of Infectious Diseases, 1980